Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

West Philadelphia native Fran Visco, who heads the National Breast Cancer Coalition, is feted at White House. When Fran Visco ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Arvinas (ARVN) announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...